XML 33 R22.htm IDEA: XBRL DOCUMENT
v3.24.3

Segment Disclosures | 9 Months Ended
--- | ---
Sep. 30, 2024
Segment Reporting [Abstract] |
Segment Disclosures | Segment Disclosures The Company’s reportable segments, based on how its CODM evaluates the business and allocates resources, are as follows: (i) outpatient medical, (ii) lab, and (iii) CCRC. The Company has non-reportable segments that are comprised primarily of: (i) an interest in an unconsolidated joint venture that owns 19 senior housing assets (the “SWF SH JV”) and (ii) loans receivable. These non-reportable segments have been presented on an aggregate basis within the Notes to the Consolidated Financial Statements herein. The accounting policies of the segments are the same as those described in Note 2 to the Consolidated Financial Statements in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the SEC, as updated by Note 2 herein. The Company evaluates performance based on property Adjusted NOI. Adjusted NOI is defined as real estate revenues (inclusive of rental and related revenues, resident fees and services, and government grant income and exclusive of interest income), less property level operating expenses; Adjusted NOI excludes all other financial statement amounts included in net income (loss). Adjusted NOI eliminates the effects of straight-line rents, amortization of market lease intangibles, termination fees, actuarial reserves for insurance claims that have been incurred but not reported, and the impact of deferred community fee income and expense. Adjusted NOI is calculated as Adjusted NOI from consolidated properties, plus the Company’s share of Adjusted NOI from unconsolidated joint ventures (calculated by applying the Company’s actual ownership percentage for the period), less noncontrolling interests’ share of Adjusted NOI from consolidated joint ventures (calculated by applying the Company’s actual ownership percentage for the period). Management utilizes its share of Adjusted NOI in assessing its performance as the Company has various joint ventures that contribute to its performance. The Company does not control its unconsolidated joint ventures, and the Company’s share of amounts from unconsolidated joint ventures does not represent the Company’s legal claim to such items. Adjusted NOI is used to evaluate performance because it provides relevant and useful information by reflecting only income and operating expense items that are incurred at the property level and presenting it on an unlevered basis. The following tables summarize information for the reportable segments (in thousands). For the three months ended September 30, 2024:
|  | Outpatient Medical |  | Lab |  | CCRC |  |  |  |  |  | Total
Total revenues |  | $ | 317,659 |  |  | $ | 225,592 |  |  | $ | 142,845 |  |  |  |  |  |  | $ | 686,096 |
Healthpeak’s share of unconsolidated joint venture total revenues |  | 7,065 |  |  | 5,242 |  |  | — |  |  |  |  |  |  | 12,307 |
Noncontrolling interests’ share of consolidated joint venture total revenues |  | (9,734) |  |  | — |  |  | — |  |  |  |  |  |  | (9,734) |
Operating expenses |  | (106,484) |  |  | (64,075) |  |  | (109,720) |  |  |  |  |  |  | (280,279) |
Healthpeak’s share of unconsolidated joint venture operating expenses |  | (2,832) |  |  | (1,811) |  |  | — |  |  |  |  |  |  | (4,643) |
Noncontrolling interests’ share of consolidated joint venture operating expenses |  | 2,851 |  |  | — |  |  | — |  |  |  |  |  |  | 2,851 |
Adjustments to NOI(1) |  | (11,020) |  |  | (16,900) |  |  | 95 |  |  |  |  |  |  | (27,825) |
Adjusted NOI for reportable segments |  | $ | 197,505 |  |  | $ | 148,048 |  |  | $ | 33,220 |  |  |  |  |  |  | $ | 378,773 |
Plus: Adjustments to NOI(1) |  |  |  |  |  |  |  |  |  |  |  | 27,825 |
Interest income and other |  |  |  |  |  |  |  |  |  |  |  | 14,301 |
Interest expense |  |  |  |  |  |  |  |  |  |  |  | (74,105) |
Depreciation and amortization |  |  |  |  |  |  |  |  |  |  |  | (280,019) |
General and administrative |  |  |  |  |  |  |  |  |  |  |  | (23,216) |
Transaction and merger-related costs |  |  |  |  |  |  |  |  |  |  |  | (7,134) |
Impairments and loan loss reserves, net |  |  |  |  |  |  |  |  |  |  |  | (441) |
Gain (loss) on sales of real estate, net |  |  |  |  |  |  |  |  |  |  |  | 62,325 |
Other income (expense), net |  |  |  |  |  |  |  |  |  |  |  | 982 |
Less: Healthpeak’s share of unconsolidated joint venture NOI |  |  |  |  |  |  |  |  |  |  |  | (7,664) |
Plus: Noncontrolling interests’ share of consolidated joint venture NOI |  |  |  |  |  |  |  |  |  |  |  | 6,883 |
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures |  |  |  |  |  |  |  |  |  |  |  | $ | 98,510 |
_______________________________________ (1)Represents straight-line rents, amortization of market lease intangibles, net, actuarial reserves for insurance claims that have been incurred but not reported, deferral of community fees, and termination fees. Includes the Company’s share of income (loss) generated by unconsolidated joint ventures and excludes noncontrolling interests’ share of income (loss) generated by consolidated joint ventures. For the three months ended September 30, 2023:
|  | Outpatient Medical |  | Lab |  | CCRC |  |  |  |  |  | Total
Total revenues |  | $ | 191,016 |  |  | $ | 226,059 |  |  | $ | 133,808 |  |  |  |  |  |  | $ | 550,883 |
Healthpeak’s share of unconsolidated joint venture total revenues |  | 746 |  |  | 2,425 |  |  | — |  |  |  |  |  |  | 3,171 |
Noncontrolling interests’ share of consolidated joint venture total revenues |  | (8,735) |  |  | (154) |  |  | — |  |  |  |  |  |  | (8,889) |
Operating expenses |  | (67,693) |  |  | (60,268) |  |  | (104,773) |  |  |  |  |  |  | (232,734) |
Healthpeak’s share of unconsolidated joint venture operating expenses |  | (301) |  |  | (958) |  |  | — |  |  |  |  |  |  | (1,259) |
Noncontrolling interests’ share of consolidated joint venture operating expenses |  | 2,474 |  |  | 33 |  |  | — |  |  |  |  |  |  | 2,507 |
Adjustments to NOI(1) |  | (3,547) |  |  | (9,842) |  |  | — |  |  |  |  |  |  | (13,389) |
Adjusted NOI for reportable segments |  | $ | 113,960 |  |  | $ | 157,295 |  |  | $ | 29,035 |  |  |  |  |  |  | $ | 300,290 |
Plus: Adjustments to NOI(1) |  |  |  |  |  |  |  |  |  |  |  | 13,389 |
Interest income and other |  |  |  |  |  |  |  |  |  |  |  | 5,360 |
Interest expense |  |  |  |  |  |  |  |  |  |  |  | (50,510) |
Depreciation and amortization |  |  |  |  |  |  |  |  |  |  |  | (184,559) |
General and administrative |  |  |  |  |  |  |  |  |  |  |  | (23,093) |
Transaction and merger-related costs |  |  |  |  |  |  |  |  |  |  |  | (36) |
Impairments and loan loss reserves, net |  |  |  |  |  |  |  |  |  |  |  | 550 |
Other income (expense), net |  |  |  |  |  |  |  |  |  |  |  | 1,481 |
Less: Healthpeak’s share of unconsolidated joint venture NOI |  |  |  |  |  |  |  |  |  |  |  | (1,912) |
Plus: Noncontrolling interests’ share of consolidated joint venture NOI |  |  |  |  |  |  |  |  |  |  |  | 6,382 |
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures |  |  |  |  |  |  |  |  |  |  |  | $ | 67,342 |
_______________________________________ (1)Represents straight-line rents, amortization of market lease intangibles, net, actuarial reserves for insurance claims that have been incurred but not reported, deferral of community fees, and termination fees. Includes the Company’s share of income (loss) generated by unconsolidated joint ventures and excludes noncontrolling interests’ share of income (loss) generated by consolidated joint ventures. For the nine months ended September 30, 2024:
|  | Outpatient Medical |  | Lab |  | CCRC |  |  |  |  |  | Total |
Total revenues |  | $ | 888,446 |  |  | $ | 663,619 |  |  | $ | 422,512 |  |  |  |  |  |  | $ | 1,974,577 |  |
Healthpeak’s share of unconsolidated joint venture total revenues |  | 16,707 |  |  | 14,404 |  |  | — |  |  |  |  |  |  | 31,111 |  |
Noncontrolling interests’ share of consolidated joint venture total revenues |  | (27,952) |  |  | (196) |  |  | — |  |  |  |  |  |  | (28,148) |  |
Operating expenses |  | (299,455) |  |  | (177,571) |  |  | (320,809) |  |  |  |  |  |  | (797,835) |  |
Healthpeak’s share of unconsolidated joint venture operating expenses |  | (6,380) |  |  | (4,663) |  |  | — |  |  |  |  |  |  | (11,043) |  |
Noncontrolling interests’ share of consolidated joint venture operating expenses |  | 7,889 |  |  | 52 |  |  | — |  |  |  |  |  |  | 7,941 |  |
Adjustments to NOI(1) |  | (27,573) |  |  | (51,624) |  |  | (1,645) |  |  |  |  |  |  | (80,842) |  |
Adjusted NOI for reportable segments |  | $ | 551,682 |  |  | $ | 444,021 |  |  | $ | 100,058 |  |  |  |  |  |  | $ | 1,095,761 |  |
Plus: Adjustments to NOI(1) |  |  |  |  |  |  |  |  |  |  |  | 80,842 |  |
Interest income and other |  |  |  |  |  |  |  |  |  |  |  | 27,884 |  |
Interest expense |  |  |  |  |  |  |  |  |  |  |  | (209,922) |  |
Depreciation and amortization |  |  |  |  |  |  |  |  |  |  |  | (782,736) |  |
General and administrative |  |  |  |  |  |  |  |  |  |  |  | (73,233) |  |
Transaction and merger-related costs |  |  |  |  |  |  |  |  |  |  |  | (122,113) |  |
Impairments and loan loss reserves, net |  |  |  |  |  |  |  |  |  |  |  | (11,346) |  |
Gain (loss) on sales of real estate, net |  |  |  |  |  |  |  |  |  |  |  | 187,624 |  |
Other income (expense), net |  |  |  |  |  |  |  |  |  |  |  | 83,502 |  |
Less: Healthpeak’s share of unconsolidated joint venture NOI |  |  |  |  |  |  |  |  |  |  |  | (20,068) |  |
Plus: Noncontrolling interests’ share of consolidated joint venture NOI |  |  |  |  |  |  |  |  |  |  |  | 20,207 |  |
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures |  |  |  |  |  |  |  |  |  |  |  | $ | 276,402 |  |
______________________________________________________________________________ (1)Represents straight-line rents, amortization of market lease intangibles, net, actuarial reserves for insurance claims that have been incurred but not reported, deferral of community fees, and termination fees. Includes the Company’s share of income (loss) generated by unconsolidated joint ventures and excludes noncontrolling interests’ share of income (loss) generated by consolidated joint ventures. For the nine months ended September 30, 2023:
|  | Outpatient Medical |  | Lab |  | CCRC |  |  |  |  |  | Total
Total revenues |  | $ | 564,644 |  |  | $ | 654,829 |  |  | $ | 391,076 |  |  |  |  |  |  | $ | 1,610,549 |
Government grant income(1) |  | — |  |  | — |  |  | 184 |  |  |  |  |  |  | 184 |
Healthpeak’s share of unconsolidated joint venture total revenues |  | 2,245 |  |  | 6,519 |  |  | — |  |  |  |  |  |  | 8,764 |
Noncontrolling interests’ share of consolidated joint venture total revenues |  | (26,364) |  |  | (449) |  |  | — |  |  |  |  |  |  | (26,813) |
Operating expenses |  | (197,442) |  |  | (172,666) |  |  | (307,551) |  |  |  |  |  |  | (677,659) |
Healthpeak’s share of unconsolidated joint venture operating expenses |  | (895) |  |  | (2,987) |  |  | — |  |  |  |  |  |  | (3,882) |
Noncontrolling interests’ share of consolidated joint venture operating expenses |  | 7,477 |  |  | 108 |  |  | — |  |  |  |  |  |  | 7,585 |
Adjustments to NOI(2) |  | (11,373) |  |  | (25,618) |  |  | (679) |  |  |  |  |  |  | (37,670) |
Adjusted NOI for reportable segments |  | $ | 338,292 |  |  | $ | 459,736 |  |  | $ | 83,030 |  |  |  |  |  |  | $ | 881,058 |
Plus: Adjustments to NOI(2) |  |  |  |  |  |  |  |  |  |  |  | 37,670 |
Interest income and other |  |  |  |  |  |  |  |  |  |  |  | 16,802 |
Interest expense |  |  |  |  |  |  |  |  |  |  |  | (147,547) |
Depreciation and amortization |  |  |  |  |  |  |  |  |  |  |  | (561,357) |
General and administrative |  |  |  |  |  |  |  |  |  |  |  | (73,576) |
Transaction and merger-related costs |  |  |  |  |  |  |  |  |  |  |  | (3,098) |
Impairments and loan loss reserves, net |  |  |  |  |  |  |  |  |  |  |  | 156 |
Gain (loss) on sales of real estate, net |  |  |  |  |  |  |  |  |  |  |  | 86,463 |
Other income (expense), net |  |  |  |  |  |  |  |  |  |  |  | 4,208 |
Less: Government grant income |  |  |  |  |  |  |  |  |  |  |  | (184) |
Less: Healthpeak’s share of unconsolidated joint venture NOI |  |  |  |  |  |  |  |  |  |  |  | (4,882) |
Plus: Noncontrolling interests’ share of consolidated joint venture NOI |  |  |  |  |  |  |  |  |  |  |  | 19,228 |
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures |  |  |  |  |  |  |  |  |  |  |  | $ | 254,941 |
______________________________________________________________________________ (1)Represents government grant income received under the CARES Act, which is recorded in other income (expense), net in the Consolidated Statements of Operations (see Note 2). (2)Represents straight-line rents, amortization of market lease intangibles, net, actuarial reserves for insurance claims that have been incurred but not reported, deferral of community fees, and termination fees. Includes the Company’s share of income (loss) generated by unconsolidated joint ventures and excludes noncontrolling interests’ share of income (loss) generated by consolidated joint ventures. The following table summarizes the Company’s revenues by reportable segment (in thousands):
|  | Three Months Ended September 30, |  | Nine Months Ended September 30,
Segment |  | 2024 |  | 2023 |  | 2024 |  | 2023
Outpatient medical |  | $ | 317,659 |  |  | $ | 191,016 |  |  | $ | 888,446 |  |  | $ | 564,644 |
Lab |  | 225,592 |  |  | 226,059 |  |  | 663,619 |  |  | 654,829 |
CCRC |  | 142,845 |  |  | 133,808 |  |  | 422,512 |  |  | 391,076 |
Total revenues for reportable segments |  | 686,096 |  |  | 550,883 |  |  | 1,974,577 |  |  | 1,610,549 |
Interest income and other |  | 14,301 |  |  | 5,360 |  |  | 27,884 |  |  | 16,802 |
Total revenues |  | $ | 700,397 |  |  | $ | 556,243 |  |  | $ | 2,002,461 |  |  | $ | 1,627,351 |
See Note 3 for impacts to segment assets as a result of the Merger. See these Notes to the Consolidated Financial Statements for other significant transactions impacting the Company’s segment assets during the periods presented.

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 10: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContent Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration